Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cipla Ltd.

www.cipla.com

Latest From Cipla Ltd.

US Phlow Model And Drug Nationalism: Do Indian Firms Need To Be Watchful?

The new US public benefit pharma manufacturing firm Phlow has received significant federal funding in a bid to improve domestic supply security. Scrip speaks to prominent executives in India's industry over whether this model, if widely replicated, could put at risk the clout and market access plans of the Indian generic industry, a major supplier to the US market. 

Commercial Strategy

Cipla Propels 'Lung Leadership' Plans

Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.

Strategy Sales & Earnings

Cipla Propels Lung Leadership Plans, Reimagines Operating Models

Cipla’s fourth-quarter 2020 sales were hit because of COVID-19- related dispatch challenges, though it remains upbeat about the prospects of interchangeable albuterol and the latest filing for generic Advair Diskus as part of its quest for lung leadership.

Commercial Sales & Earnings

Cipla Files ANDA For Advair Rival

Cipla has revealed that it has now filed its ANDA for a US rival to Advair Diskus. The FDA is already considering Hikma’s generic, while Mylan’s Wixela Inhub version has been on the market for well over a year.

Generic Drugs United States
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
  • Therapeutic Areas
  • Cancer
  • Cardiovascular
  • Dermatology
  • Gynecological, Urological
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Ophthalmic
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Cipla Ltd.
  • Senior Management
  • Umang Vohra, Managing Dir. & Global CEO
    Kedar Upadhye, Global CFO
  • Contact Info
  • Cipla Ltd.
    Phone: (91) 22 24826000
    Peninsula Business Park
    Lower Parel
    Mumbai, 400008
    India
UsernamePublicRestriction

Register